Glatiramer acetate

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 01:07, May 11, 2022 by Notjusttired (talk | contribs) (Text replacement - "\[\[Category(.*)\]\] <references \/>" to "{{Reflist}} Category$1")

Copaxone or glatopa, and glatiramer, its generic form, is a drug licensed to reduce relapses in patients with multiple sclerosis.[1]

ME/CFS[edit | edit source]

Load video
YouTube
Dr. Ron Davis on Copaxone in ME/CFS. Inaugural Harvard Symposium, Sep 2019.

Ron Davis of the Open Medicine Foundation reports that when the nanoneedle electrical impedance test on ME/CFS cells was used, Copaxone made the cells respond in the same way as healthy cells did, suggesting it is a potential treatment for ME/CFS.[2]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ "Copaxone: Uses, Dosage, Side Effects". Drugs.com. Retrieved April 30, 2019.
  2. ↑ Davis, Ron (September 2019). "Dr. Ron Davis Presents on ME/CFS Research Activities at Stanford at Inaugural Harvard Symposium". Retrieved September 8, 2019.

nanoneedle A device with microscopic dimensions which measures electrical impedance across a blood cell. According to Ron Davis, the nanoneedle measured increased electrical impedance in the blood cells of 10 ME/CFS patients when stressed with salt, but not in healthy controls. Accordingly, this device has been proposed as a potential diagnostic test to distinguish ME/CFS patients from healthy controls. (Learn more: www.omf.ngo)

Retrieved from "https://me-pedia.org/w/index.php?title=Glatiramer_acetate&oldid=109682"